Cynata Therapeutics Limited Stock Market Value
| CYYNF Stock | USD 0.22 0.00 0.00% |
| Symbol | Cynata |
Cynata Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cynata Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cynata Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Cynata Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Cynata Therapeutics Limited or generate 0.0% return on investment in Cynata Therapeutics over 90 days. Cynata Therapeutics is related to or competes with Defence Therapeutics, Medical Developments, and Novacyt SA. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem ... More
Cynata Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cynata Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cynata Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1569 | |||
| Maximum Drawdown | 46.67 |
Cynata Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cynata Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cynata Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cynata Therapeutics historical prices to predict the future Cynata Therapeutics' volatility.| Risk Adjusted Performance | 0.1441 | |||
| Jensen Alpha | 1.07 | |||
| Total Risk Alpha | 0.5949 | |||
| Treynor Ratio | 16.03 |
Cynata Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1441 | |||
| Market Risk Adjusted Performance | 16.04 | |||
| Mean Deviation | 2.11 | |||
| Coefficient Of Variation | 596.28 | |||
| Standard Deviation | 6.47 | |||
| Variance | 41.92 | |||
| Information Ratio | 0.1569 | |||
| Jensen Alpha | 1.07 | |||
| Total Risk Alpha | 0.5949 | |||
| Treynor Ratio | 16.03 | |||
| Maximum Drawdown | 46.67 | |||
| Skewness | 6.33 | |||
| Kurtosis | 41.44 |
Cynata Therapeutics Backtested Returns
Cynata Therapeutics appears to be out of control, given 3 months investment horizon. Cynata Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. By analyzing Cynata Therapeutics' technical indicators, you can evaluate if the expected return of 0.73% is justified by implied risk. Please makes use of Cynata Therapeutics' Standard Deviation of 6.47, mean deviation of 2.11, and Risk Adjusted Performance of 0.1441 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cynata Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 0.0671, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cynata Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cynata Therapeutics is expected to be smaller as well. Please check Cynata Therapeutics' variance and kurtosis , to make a quick decision on whether Cynata Therapeutics' price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Cynata Therapeutics Limited has no correlation between past and present. Overlapping area represents the amount of predictability between Cynata Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cynata Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Cynata Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.